BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17031243)

  • 41. Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A Rare Case Report.
    Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Piyawong W; Himakhun W; Bhamarapravatana K
    J Med Assoc Thai; 2016 Jul; 99 Suppl 4():S281-6. PubMed ID: 29927186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
    Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
    PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma.
    Lewandrowski KB; Southern JF; Pins MR; Compton CC; Warshaw AL
    Ann Surg; 1993 Jan; 217(1):41-7. PubMed ID: 8424699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ovarian mucinous tumors arising from mature cystic teratomas--a molecular genetic approach for understanding the cellular origin.
    Fujii K; Yamashita Y; Yamamoto T; Takahashi K; Hashimoto K; Miyata T; Kawai K; Kikkawa F; Toyokuni S; Nagasaka T
    Hum Pathol; 2014 Apr; 45(4):717-24. PubMed ID: 24485845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benign Ovarian Tumors in Pregnancy: A Case Report of Metachronous Ipsilateral Recurrent Mucinous Cystadenoma in Initial Pregnancy and Mature Cystic Teratoma in Subsequent Pregnancy.
    Schreck AM; Mikdachi HF
    Cureus; 2019 Jan; 11(1):e3818. PubMed ID: 30868032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers.
    Callet N; Delaunay J; Pichon MF
    Eur J Gynaecol Oncol; 2000; 21(2):135-40. PubMed ID: 10843471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
    Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
    Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
    Yoshida A; Sarian LO; Andrade LA; Pignataro F; Pinto GA; Derchain SF
    Int J Gynecol Cancer; 2007; 17(3):607-14. PubMed ID: 17504375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and pathologic evaluation of 342 benign ovarian tumors.
    Portuondo JA; Gimenez B; Rivera JM; Garriga J; Alegre A
    Int J Gynaecol Obstet; 1984 Aug; 22(4):263-7. PubMed ID: 6152793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
    Yang JM; Southern JF; Warshaw AL; Lewandrowski KB
    Am J Surg; 1996 Jan; 171(1):126-9; discussion 129-30. PubMed ID: 8554126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benign epithelial ovarian tumors.
    Tuncer ZS; Günalp S; Aksu T; Ayhan A
    Eur J Gynaecol Oncol; 1998; 19(4):391-3. PubMed ID: 9744734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ultrastructural study of benign, low-malignant potential (LMP), and malignant ovarian tumors.
    Ishioka S; Sagae S; Ito E; Kudo R
    Med Electron Microsc; 2004 Mar; 37(1):37-44. PubMed ID: 15057603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metachronous benign ovarian tumors are not uncommon in children.
    Taskinen S; Urtane A; Fagerholm R; Lohi J; Taskinen M
    J Pediatr Surg; 2014 Apr; 49(4):543-5. PubMed ID: 24726109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Ferritin levels of ascites and the contents of cystic ovarian tumors--possibilities of ferritin production and secretion by malignant tumor cells].
    Okamoto M; Fukasawa H; Hirata F; Hoshi S
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):240-6. PubMed ID: 6696460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
    Kim DJ; Lee MH; Park TI; Bae HI
    J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinicomorphological Spectrum of Ovarian Cystic Lesions.
    Dhakal R; Makaju R; Bastakoti R
    Kathmandu Univ Med J (KUMJ); 2016; 14(53):13-16. PubMed ID: 27892434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
    Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
    Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins.
    Wang Y; Schwartz LE; Anderson D; Lin MT; Haley L; Wu RC; Vang R; Shih IeM; Kurman RJ
    Oncotarget; 2015 Sep; 6(26):22949-58. PubMed ID: 26355245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.